BlackThorn Therapeutics, Inc.

Release Summary

BlackThorn Therapeutics, a clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, announced that it has closed a $40 million Series A.

BlackThorn Therapeutics, Inc.